Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-09-21 Purchase | 2023-09-25 4:21 pm | GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer | 65,403 | $1.38 | $90,256 | 375,403 (Direct) | View |
2023-05-17 Sale | 2023-05-18 4:27 pm | GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO | 3,700 | $1.95 | $7,215 | 53,143 (Direct) | View |
2023-05-10 Purchase | 2023-05-11 5:08 pm | GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director | 30,000 | $1.56 | $46,800 | 93,250 (Direct) | View |
2023-05-08 Purchase | 2023-05-09 5:00 pm | GLYCOMIMETICS INC | GLYC | Johnson Bruce S SVP & Chief Commercial Officer | 13,500 | $1.57 | $21,195 | 138,980 (Direct) | View |
2023-02-24 Purchase | 2023-02-28 5:33 pm | GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner | 100,000 | $1.7 | $170,000 | 8,589,064 (Direct) | View |
2023-02-21 Purchase | 2023-02-23 6:23 pm | GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner | 400,000 | $1.7806 | $712,255 | 8,489,064 (Direct) | View |
2023-02-15 Purchase | 2023-02-17 5:29 pm | GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner | 1,515,266 | $1.9983 | $3,027,929 | 8,089,064 (Direct) | View |
2023-02-09 Purchase | 2023-02-13 5:45 pm | GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner | 11,451 | $3.2419 | $37,123 | 6,573,798 (Direct) | View |
2023-01-25 Sale | 2023-01-27 5:15 pm | GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner | 3,652,016 | $3.1447 | $11,484,515 | 2,237,196 (Indirect) | View |
2023-01-05 Sale | 2023-01-06 6:35 pm | GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner | 71,362 | $2.7586 | $196,859 | 3,881,933 (Indirect) | View |
2022-12-30 Sale | 2023-01-04 5:26 pm | GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner | 398,133 | $2.9786 | $1,185,886 | 3,914,072 (Indirect) | View |
2022-12-22 Purchase | 2022-12-27 6:41 pm | GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer | 110,000 | $2.25 | $247,500 | 310,000 (Direct) | View |
2022-11-17 Purchase | 2022-11-18 4:01 pm | GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director | 20,000 | $1.87 | $37,400 | 63,250 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-01-12 Option Award | 2024-01-17 4:05 pm | N/A 2034-01-11 | GLYCOMIMETICS INC | GLYC | Johnson Bruce S SVP & Chief Commercial Officer | 250,000 | $0 | 250,000 (Direct) | View |
2024-01-12 Option Award | 2024-01-17 4:05 pm | N/A 2034-01-11 | GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer | 695,000 | $0 | 695,000 (Direct) | View |
2024-01-12 Option Award | 2024-01-17 4:05 pm | N/A 2034-01-11 | GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer | 250,000 | $0 | 250,000 (Direct) | View |
2024-01-12 Option Award | 2024-01-17 4:05 pm | N/A 2034-01-11 | GLYCOMIMETICS INC | GLYC | Rath Chinmaya SVP and Chief Business Officer | 250,000 | $0 | 250,000 (Direct) | View |
2024-01-12 Option Award | 2024-01-17 4:05 pm | N/A 2034-01-11 | GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO | 250,000 | $0 | 250,000 (Direct) | View |
2023-12-29 Option Award | 2024-01-02 4:05 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director | 5,191 | $2.36 | 58,608 (Direct) | View |
2023-12-29 Option Award | 2024-01-02 4:05 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | King Rachel K. Director | 4,238 | $2.36 | 657,502 (Direct) | View |
2023-12-29 Option Award | 2024-01-02 4:05 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director | 5,827 | $2.36 | 31,741 (Direct) | View |
2023-09-30 Option Award | 2023-10-03 4:15 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director | 9,167 | $1.5 | 25,914 (Direct) | View |
2023-09-30 Option Award | 2023-10-03 4:05 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director | 8,167 | $1.5 | 53,417 (Direct) | View |
2023-09-30 Option Award | 2023-10-03 4:05 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | King Rachel K. Director | 6,667 | $1.5 | 653,264 (Direct) | View |
2023-06-01 Exercise | 2023-06-02 4:10 pm | N/A 2032-05-17 | GLYCOMIMETICS INC | GLYC | Koenig Scott Director | 21,000 | $0 | 36,750 (Direct) | View |
2023-06-01 Exercise | 2023-06-02 4:10 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Koenig Scott Director | 21,000 | $0.6 | 36,750 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:27 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | King Rachel K. Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:25 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:24 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | Koenig Scott Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:23 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:21 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | PEARSON TIMOTHY R Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:20 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director | 35,000 | $0 | 35,000 (Direct) | View |
2023-05-19 Option Award | 2023-05-22 4:18 pm | N/A 2033-05-18 | GLYCOMIMETICS INC | GLYC | Jackson Scott Thomas Director | 35,000 | $0 | 35,000 (Direct) | View |
Ownership | 2023-03-31 4:36 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Rath Chinmaya SVP and Chief Business Officer | 0 | $0 | 311,178 (Direct) | View |
Ownership | 2023-03-31 4:34 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Johnson Bruce S SVP & Chief Commercial Officer | 0 | $0 | 560,480 (Direct) | View |
Ownership | 2023-02-13 5:40 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner | 0 | $0 | 6,562,347 (Direct) | View |
Ownership | 2023-02-06 4:13 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | King Rachel K. Director | 0 | $0 | 646,597 (Indirect) | View |
2022-02-15 Ownership | 2023-02-06 4:13 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | King Rachel K. Director | 19,141 | $0 | 646,597 (Direct) | View |
2023-01-27 Exercise | 2023-01-30 4:13 pm | N/A N/A | GLYCOMIMETICS INC | GLYC | Koenig Scott Director | 10,500 | $2.55 | 15,750 (Direct) | View |
2023-01-27 Exercise | 2023-01-30 4:13 pm | N/A 2031-05-17 | GLYCOMIMETICS INC | GLYC | Koenig Scott Director | 10,500 | $0 | 15,750 (Direct) | View |
2023-01-19 Option Award | 2023-01-20 4:08 pm | N/A 2033-01-18 | GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO | 246,300 | $0 | 246,300 (Direct) | View |
2023-01-19 Option Award | 2023-01-20 4:04 pm | N/A 2033-01-18 | GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer | 651,200 | $0 | 651,200 (Direct) | View |
2023-01-19 Option Award | 2023-01-20 4:02 pm | N/A 2033-01-18 | GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer | 244,800 | $0 | 244,800 (Direct) | View |